Geron Corporation (GERN)

NMS – Цена в реальном времени. Валюта: USD

1.40

+0.01 (0.72%)

При закрытии: May 12, 2026, 4:00 PM EDT

1.42

+0.02 (1.42%)

После закрытия: May 12, 2026, 7:59 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Geron Corporation (GERN)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Geron Corporation (GERN)

First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026

Geron Corporation (GERN) Q1 2026 Earnings Call Transcript

Geron (GERN) Reports Q1 Loss, Beats Revenue Estimates

Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights

Geron Plans to Present at Upcoming Investor Conferences

Geron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Видео

No Data

Пресс-релизы

First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026

Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Search stocks

Geron Corporation (GERN)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Geron Corporation (GERN)

First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026

Geron Corporation (GERN) Q1 2026 Earnings Call Transcript

Geron (GERN) Reports Q1 Loss, Beats Revenue Estimates

Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights

Geron Plans to Present at Upcoming Investor Conferences

Geron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Видео

No Data

Пресс-релизы

First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026

Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)